Research programme: phosphatidylinositol 3-kinase inhibitors - Cerylid

Drug Profile

Research programme: phosphatidylinositol 3-kinase inhibitors - Cerylid

Alternative Names: CBL 1155; CBL 1309; KN 309

Latest Information Update: 07 Feb 2011

Price : $50

At a glance

  • Originator Cerylid Biosciences
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammation; Thrombosis

Most Recent Events

  • 15 Jun 2005 Compounds from this programme are available for licensing (http://www.cerylid.com.au)
  • 17 May 2005 Preclinical trials in Thrombosis in Australia (PO)
  • 17 May 2005 Preclinical trials in Inflammation in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top